Gilead Sciences (GILD) Rises Yet Lags Behind Market: Some Facts Worth Knowing

Gilead Sciences (GILD) closed the most recent trading day at $139.37, moving +2.22% from the previous trading session. This move lagged the S&P 500's daily gain of 2.91%. Meanwhile, the Dow gained 2.49%, and the Nasdaq, a tech-heavy index, added 3.83%. Shares of the HIV and hepatitis C drugmaker have depreciated by 9.12% over the course of the past month, outperforming the Medical sector's loss of 9.63%, and lagging the S&P 500's loss of 7.64%.Analysts and investors alike will be keeping a close eye on the performance of Gilead Sciences in its upcoming earnings disclosure. The company is predicted to post an EPS of $1.86, indicating a 2.76% growth compared to the equivalent quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $6.86 billion, indicating a 2.93% upward movement from the same quarter last year. For the full year, the Zacks Consensus Estimates are projecting earnings of $8.66 per share and revenue of $30.18 billion, which would represent changes of +6.26% and +2.5%, respectively, from the prior year. Investors should also pay attention to any latest changes in analyst estimates for Gilead Sciences. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits. Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Gilead Sciences currently has a Zacks Rank of #3 (Hold). With respect to valuation, Gilead Sciences is currently being traded at a Forward P/E ratio of 15.75. This expresses a discount compared to the average Forward P/E of 17.84 of its industry. It's also important to note that GILD currently trades at a PEG ratio of 1.79. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. As of the close of trade yesterday, the Medical - Biomedical and Genetics industry held an average PEG ratio of 1.49. The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 148, putting it in the bottom 40% of all 250+ industries. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions. Research Chief Names "Single Best Pick to Double"From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Gilead Sciences, Inc. (GILD): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks